Company Analysis
Sign in

Climb Bio, Inc. (CLYM)

Nasdaq: CLYM · Pharmaceutical Preparations · Wellesley Hills, MA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.8
◀ Past 5.3● Present 4.5▶ Future 4.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 5, 2026Mar 25, 2025Mar 28, 2024Mar 6, 2023Mar 7, 2022·
For lenders
Interest and dividend income·8,1324,620···
Interest and investment income8,3238,132····
Research and development46,71314,336r15,41126,21423,322r8,769
General and administrative21,17016,02524,86418,92112,3502,425
Total operating expenses67,88382,02040,27545,13535,67220,925
Operating income-67,883-82,020-40,275-45,135-35,672-20,925
Other income (expense), net8,0328,1235,156-109-11,808257
Income tax expense000000
Net income including non-controlling interests-59,851-73,897-35,119-45,244-47,480-20,668
Net income-59,851-73,897-35,119-45,244-47,480-20,668
Net income to common shareholders···-45,244-52,028-22,953
Earnings per share, basic-0.88-1.53-1.30-1.72-4.24·
Earnings per share, diluted-0.88-1.53-1.30-1.72-4.24·
Earnings per share, basic and diluted····-4.24-10.49
Weighted average shares, basic67,812,14548,163,30126,987,12226,311,55412,260,551·
Weighted average shares, diluted67,812,14548,163,30126,987,12226,311,55412,260,5512,187,813
Weighted average shares, basic and diluted····12,260,5512,187,813
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Interest and dividend income what its loans and securities earnedus-gaap:InterestIncomeOperating
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton CLYM · research, not advice